Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevent...

por Mikol, Daniel D., Snellman, Josefin
Publicado 2019

Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study

por Yusuf, Akeem, Chia, Victoria, Xue, Fei, Mikol, Daniel D., Bollinger, Lisa, Cangialose, Charles
Publicado 2018

A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

por Depre, Christophe, Antalik, Lubomir, Starling, Amaal, Koren, Michael, Eisele, Osaro, Lenz, Robert A., Mikol, Daniel D.
Publicado 2018

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine preven...

por Ashina, Messoud, Doležil, David, Bonner, Jo H, Zhou, Lifen, Klatt, Jan, Picard, Hernan, Mikol, Daniel D
Publicado 2020

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females

por Xu, Yang, Gabriel, Kristin, Wang, Yi, Zhou, Yanchen, Eisele, Osaro, Vutikullird, Apinya, Mikol, Daniel D., Lee, Edward
Publicado 2019

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults

por Sakai, Fumihiko, Takeshima, Takao, Tatsuoka, Yoshihisa, Hirata, Koichi, Lenz, Robert, Wang, Yi, Cheng, Sunfa, Hirama, Toshiyasu, Mikol, Daniel D.
Publicado 2019

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine

por Sakai, Fumihiko, Takeshima, Takao, Tatsuoka, Yoshihisa, Hirata, Koichi, Cheng, Sunfa, Numachi, Yotaro, Peng, Cheng, Xue, Fei, Mikol, Daniel D.
Publicado 2021

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

por Takeshima, Takao, Sakai, Fumihiko, Hirata, Koichi, Imai, Noboru, Matsumori, Yasuhiko, Yoshida, Ryuji, Peng, Cheng, Cheng, Sunfa, Mikol, Daniel D.
Publicado 2021

Efficacy and safety of erenumab in women with a history of menstrual migraine

por Pavlovic, Jelena M., Paemeleire, Koen, Göbel, Hartmut, Bonner, Jo, Rapoport, Alan, Kagan, Risa, Zhang, Feng, Picard, Hernan, Mikol, Daniel D.
Publicado 2020

Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ)

por Hareendran, Asha, Skalicky, Anne, Mannix, Sally, Lavoie, Sara, Desai, Pooja, Bayliss, Martha, Thach, Andrew V., Mikol, Daniel D., Buse, Dawn C.
Publicado 2018

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomize...

por Hirata, Koichi, Sakai, Fumihiko, Takeshima, Takao, Imai, Noboru, Matsumori, Yasuhiko, Yoshida, Ryuji, Numachi, Yotaro, Peng, Cheng, Mikol, Daniel D., Cheng, Sunfa
Publicado 2021

Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ)

por Kawata, Ariane K., Hareendran, Asha, Shaffer, Shannon, Mannix, Sally, Thach, Andrew, Desai, Pooja, Mikol, Daniel D., Ortmeier, Brian, Bayliss, Martha, Buse, Dawn C.
Publicado 2019

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

por Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Publicado 2020

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

por Ashina, Messoud, Goadsby, Peter J., Reuter, Uwe, Silberstein, Stephen, Dodick, David W., Xue, Fei, Zhang, Feng, Paiva da Silva Lima, Gabriel, Cheng, Sunfa, Mikol, Daniel D.
Publicado 2021

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study

por Lipton, Richard B., Tepper, Stewart J., Reuter, Uwe, Silberstein, Stephen, Stewart, Walter F., Nilsen, Jon, Leonardi, Dean K., Desai, Pooja, Cheng, Sunfa, Mikol, Daniel D., Lenz, Robert
Publicado 2019

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

por Ashina, Messoud, Goadsby, Peter J, Reuter, Uwe, Silberstein, Stephen, Dodick, David, Rippon, Gregory A, Klatt, Jan, Xue, Fei, Chia, Victoria, Zhang, Feng, Cheng, Sunfa, Mikol, Daniel D
Publicado 2019

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, o...

por Lipton, Richard B, Tepper, Stewart J, Silberstein, Stephen D, Kudrow, David, Ashina, Messoud, Reuter, Uwe, Dodick, David W, Zhang, Feng, Rippon, Gregory A, Cheng, Sunfa, Mikol, Daniel D
Publicado 2020

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

por Tepper, Stewart J, Ashina, Messoud, Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H, Picard, Hernan, Cheng, Sunfa, Chou, Denise E, Zhang, Feng, Klatt, Jan, Mikol, Daniel D
Publicado 2021

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies

por Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Imai, Noboru, Matsumori, Yasuhiko, Tatsuoka, Yoshihisa, Numachi, Yotaro, Yoshida, Ryuji, Peng, Cheng, Mikol, Daniel D., Lima, Gabriel Paiva da Silva, Cheng, Sunfa
Publicado 2022

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial

por Tepper, Stewart J., Diener, Hans-Christoph, Ashina, Messoud, Brandes, Jan Lewis, Friedman, Deborah I., Reuter, Uwe, Cheng, Sunfa, Nilsen, Jon, Leonardi, Dean K., Lenz, Robert A., Mikol, Daniel D.
Publicado 2019